Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

481 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-02

Study Completion Date

2024-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive favezelimab as monotherapy or favezelimab in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RP2D), as determined by dose-limiting toxicity, for favezelimab in combination with pembrolizumab or pembrolizumab and lenvatinib in participants with advanced solid tumors. Part B will also assess the efficacy of favezelimab as monotherapy; favezelimab in combination with pembrolizumab with and without chemotherapy; favezelimab in combination with pembrolizumab and lenvatinib; and favezelimab/pembrolizumab as monotherapy in expansion cohorts. Participants who have completed the initial course of treatment and have investigator-determined progressive disease may be eligible for a second course of an additional 17 cycles of study treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

NCT03918278

Neoplasms

COMPLETED PHASE1

Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)

NCT02132754

Solid Tumor

COMPLETED PHASE1

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

NCT05594043

Advanced or Metastatic Solid Tumors

COMPLETED PHASE1

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

NCT05514444

Advanced/Metastatic Solid Tumors Neoplasms

COMPLETED PHASE1

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

NCT00749502

Solid Tumors Chronic Lymphocytic Leukemia T-cell-prolymphocytic Leukemia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All participants who completed the first course were eligible for second course treatment after Sponsor consultation if there was investigator-determined progressive disease after initial treatment had been been completed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Participants were allocated to arms in a non-random fashion, except in the case of those with gastric cancer enrolled in Part B, who were randomized 1:1 between Arm 2A and Arm 2B (favezelimab 200 mg and 800 mg, respectively). Part B initiated after determination of a favezelimab recommended phase 2 dose (RP2D) from Part A.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: Favezelimab 7 mg Monotherapy

Participants received favezelimab 7 mg intravenous (IV) infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 21 mg Monotherapy

Participants received favezelimab 21 mg IV infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 70 mg Monotherapy

Participants received favezelimab 70 mg IV infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 210 mg Monotherapy

Participants received favezelimab 210 mg IV infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 700 mg Monotherapy

Participants received favezelimab 700 mg IV infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 7 mg + Pembrolizumab 200 mg

Participants received favezelimab 7 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 21 mg + Pembrolizumab 200 mg

Participants received favezelimab 21 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 70 mg + Pembrolizumab 200 mg

Participants received favezelimab 70 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 210 mg + Pembrolizumab 200 mg

Participants received favezelimab 210 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part A: Favezelimab 700 mg + Pembrolizumab 200 mg

Participants received favezelimab 700 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part B: Favezelimab 800 mg Monotherapy (Arm 1)

Participants received favezelimab 800 mg monotherapy IV infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Part B: Favezelimab 200 mg + Pembrolizumab 200 mg (Arm 2A)

Participants received favezelimab 200 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part B: Favezelimab 700 mg + Pembrolizumab 200 mg (Arm 2B)

Participants received favezelimab 700 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part B: Favezelimab 800 mg + Pembrolizumab 200 mg (Arm 2C)

Participants received favezelimab 800 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part B: Favezelimab 800 mg + Pembrolizumab 200 mg + mFOLFOX7 (Arm 3)

Participants received favezelimab 800 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS mFOLFOX7 (oxaliplatin 85 mg/m\^2 IV, leucovorin \[calcium folinate\] 400 mg/m\^2 IV, and fluorouracil \[5-FU\] 2400 mg/m\^2 IV over 46 to 48 hours, every 2 weeks \[Q2W\]).

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Oxaliplatin

Intervention Type DRUG

IV infusion

Leucovorin (Calcium Folinate)

Intervention Type DRUG

IV infusion

Fluorouracil [5-FU]

Intervention Type DRUG

IV infusion

Part B: Favezelimab 800 mg + Pembrolizumab 200 mg + FOLFIRI (Arm 4)

Participants received favezelimab 800 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS FOLFIRI (irinotecan 180 mg/m\^2 IV, leucovorin \[calcium folinate\] 400 mg/m\^2 IV and 5-FU 2400 mg/m\^2 IV over 46 to 48 hours, Q2W).

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Irinotecan

Intervention Type DRUG

IV infusion

Leucovorin (Calcium Folinate)

Intervention Type DRUG

IV infusion

Fluorouracil [5-FU]

Intervention Type DRUG

IV infusion

Part B: MK-4280A (Arm 5)

Participants received MK-4280A, a coformulation of favezelimab 800 mg + pembrolizumab 200 mg IV infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

Favezelimab/Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Part B: Favezelimab 800 mg + Pembrolizumab 200 mg + Lenvatinib 20 mg (Arm 6)

Participants received favezelimab 800 mg IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab 200 mg IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS oral lenvatinib 20 mg once daily.

Group Type EXPERIMENTAL

Favezelimab

Intervention Type BIOLOGICAL

IV infusion

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Lenvatinib

Intervention Type DRUG

Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Favezelimab

IV infusion

Intervention Type BIOLOGICAL

Pembrolizumab

IV infusion

Intervention Type BIOLOGICAL

Oxaliplatin

IV infusion

Intervention Type DRUG

Irinotecan

IV infusion

Intervention Type DRUG

Leucovorin (Calcium Folinate)

IV infusion

Intervention Type DRUG

Fluorouracil [5-FU]

IV infusion

Intervention Type DRUG

Favezelimab/Pembrolizumab

IV infusion

Intervention Type BIOLOGICAL

Lenvatinib

Oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-4280 MK-3475 KEYTRUDA® ELOXATIN® CAMPTOSAR® WELLCOVORIN® ADRUCIL® MK-4280A E7080 MK-7902 LENVIMA®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Part A and Part B: Has histologically or cytologically-confirmed metastatic solid tumor.
* Has measurable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1 criteria.
* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
* Demonstrates adequate organ function.
* If female, is not pregnant or breastfeeding, and if of child-bearing potential, is willing to use an adequate method of contraception for the course of the study and for at least 180 days after the last dose of chemotherapy, 120 days after the last dose of pembrolizumab or favezelimab, or 30 days after the last dose of lenvatinib, whichever occurs last.
* If male with a female partner(s) of child-bearing potential, both must agree to use an adequate method of contraception starting with the first dose of study drug through 95 days after the last dose of study drug.

Exclusion Criteria

* Has had chemotherapy, radiation or biological cancer therapy within 4 weeks prior to the first dose of study drug, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 or 1 from the AEs due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related \[ir\]AEs).
* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
* Has received previous treatment with another agent targeting the lymphocyte-activation gene 3 (LAG-3) receptor.
* Has received previous treatment with an immunomodulatory therapy (e.g., anti-programmed cell death-1/anti-programmed cell death-ligand 1 \[anti-PD-1/anti-PD-L1\] or cytotoxic T-lymphocyte-associated protein 4 \[CTLA 4\] agent) and was discontinued from that therapy due to a Grade 3 or higher irAE.
* Is expected to require any other form of antineoplastic therapy while on study.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy in excess of replacement doses, or on any other form of immunosuppressive medication.
* Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years. Time frame exceptions include successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer, or other in situ cancers.
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Has had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
* Has an active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.
* Has an active infection requiring therapy.
* Has history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
* Has had a prior stem cell or bone marrow transplant.
* Has a known history of or screens positive for Human Immunodeficiency Virus (HIV), active chronic or acute Hepatitis B or Hepatitis C.
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
* Is a regular user as determined by investigator judgement (including "recreational use") of any illicit drugs or has a recent history (within the last year) of substance abuse (including alcohol), at the time of signing informed consent.
* Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
* Has clinically significant heart disease that affects normal activities.
* Has received a live-virus vaccine within 30 days of planned start of study drug. Seasonal flu vaccines that do not contain live virus are permitted.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No